These findings build on the earlier Company-sponsored Phase 1b/2 study, RELEASE, 1 which established the tolerability profile of selected BXCL501 doses in opioid-dependent patients and extend those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results